Phase 1Recruiting
First-in-Human Evaluation of [11C]JMJ-129-d2 for PDE-4D Imaging in Healthy Volunteers
First-in-Human Evaluation of [11C]JMJ-129-d2 for PDE4D Imaging in Healthy Volunteers
- Sponsor
- National Institute of Mental Health (NIMH) (NIH)
- Enrolment
- 40 planned
- Conditions
- Healthy
- Interventions
- [11C]JMJ-129-d2
- Ages
- adults, older adults
- Registry
- NCT07853781
From the registry
Background: PDE-4D is a protein found in the brain. It helps control chemical signals that affect mood, memory, and thinking. Problems with PDE-4D may play a role in depression and Alzheimer disease. Being able to measure PDE-4D levels in the body would help doctors identify and manage these diseases. Researchers want to find out if a new tracer (a radioactive substance injected during imaging scans) can help them see PDE-4D in people more effectively. Objective: To test a new tracer (\[11C\]JMJ-129-d2) during imaging scans of the brain and body in healthy people. Eligibility: Healthy people aged 18 years and older. They must have been screened under protocols 01M0254 or 17M0181. Design: All participants will give samples of blood and urine. They will have a test of their heart function. A plastic tube will be inserted into a vein in their arm; the new tracer will be given through this tube. Some participants will have 1 positron emission tomography (PET)/computed tomography (CT scan of their whole body. They will lie on a padded bed that slides into a doughnut-shaped…
Primary outcomes
- Total Volume of Distribution